{"organizations": [], "uuid": "ac566bbe5a9709720445c402f1b95a42265405d1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-covance-enters-into-strategic-tech/brief-covance-enters-into-strategic-technology-agreement-with-gsk-idUSFWN1QI1N9", "country": "US", "domain_rank": 408, "title": "BRIEF-Covance Enters Into Strategic Technology Agreement With GSK", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.8, "site_type": "news", "published": "2018-03-01T05:52:00.000+02:00", "replies_count": 0, "uuid": "ac566bbe5a9709720445c402f1b95a42265405d1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-covance-enters-into-strategic-tech/brief-covance-enters-into-strategic-technology-agreement-with-gsk-idUSFWN1QI1N9", "ord_in_thread": 0, "title": "BRIEF-Covance Enters Into Strategic Technology Agreement With GSK", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "covance", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}, {"name": "reuters) - laboratory corporation of america holdings", "sentiment": "neutral"}, {"name": "labcorp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "glaxosmithkline", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Laboratory Corporation Of America Holdings:\n* COVANCE ENTERS INTO STRATEGIC TECHNOLOGY AGREEMENT WITH GSK\n* LABCORP - ‍GSK WILL USE COVANCE‘S XCELLERATE MONITORING, XCELLERATE INSIGHTS, XCELLERATE CLINICAL DATA HUB SOLUTIONS IN SOFTWARE-AS-A-SERVICE MODEL​\n* LABCORP - ‍COVANCE DRUG DEVELOPMENT BUSINESS ENTERED INTO A STRATEGIC TECHNOLOGY AGREEMENT WITH GLAXOSMITHKLINE\n* LABCORP - ‍COVANCE WILL SUPPORT GSK WITH IMPLEMENTATION, STARTING IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T05:52:00.000+02:00", "crawled": "2018-03-01T21:01:59.000+02:00", "highlightTitle": ""}